Neoadjuvant hormonal treatment before radical prostatectomy

R. B. Watson, M. S. Soloway

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Randomized trials evaluating the use of androgen deprivation therapy (ADT) before radical prostatectomy have consistently shown significant decreases in prostate volume and in serum prostate-specific antigen (PSA) levels. All but one study have reported that hormonal pretreatment significantly reduces the incidence of positive surgical margins. However, androgen deprivation does not significantly influence seminal vesicle extension or lymph node involvement nor does it affect tumor grade. The fibrotic reactions that sometimes result from hormonal pretreatment can increase the difficulty of surgery but this has not been emaciated with a higher incidence of perioperative or postoperative complications. In closely monitored clinical trials, bothersome side effects of neoadjuvant hormonal therapy have been limited. Issues that remain to be addressed are the optimal duration of neoadjuvant treatment and whether the benefits of such therapy will translate into improved disease-free survival. At this time, patients with clinical stage T2b disease, PSA elevations greater than 10 to 20 ng/mL, and a high Gleason grade may be considered candidates for neoadjuvant hormonal treatment before surgery.

Original languageEnglish
Pages (from-to)48-56
Number of pages9
JournalSeminars in Urologic Oncology
Volume14
Issue number2 SUPPL. 2
StatePublished - Jun 5 1996
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Prostatectomy
Prostate-Specific Antigen
Androgens
Seminal Vesicles
Incidence
Disease-Free Survival
Prostate
Lymph Nodes
Clinical Trials
Therapeutics
Serum
Neoplasms

Keywords

  • androgen deprivation therapy
  • Prostate cancer
  • radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

Watson, R. B., & Soloway, M. S. (1996). Neoadjuvant hormonal treatment before radical prostatectomy. Seminars in Urologic Oncology, 14(2 SUPPL. 2), 48-56.

Neoadjuvant hormonal treatment before radical prostatectomy. / Watson, R. B.; Soloway, M. S.

In: Seminars in Urologic Oncology, Vol. 14, No. 2 SUPPL. 2, 05.06.1996, p. 48-56.

Research output: Contribution to journalArticle

Watson, RB & Soloway, MS 1996, 'Neoadjuvant hormonal treatment before radical prostatectomy', Seminars in Urologic Oncology, vol. 14, no. 2 SUPPL. 2, pp. 48-56.
Watson RB, Soloway MS. Neoadjuvant hormonal treatment before radical prostatectomy. Seminars in Urologic Oncology. 1996 Jun 5;14(2 SUPPL. 2):48-56.
Watson, R. B. ; Soloway, M. S. / Neoadjuvant hormonal treatment before radical prostatectomy. In: Seminars in Urologic Oncology. 1996 ; Vol. 14, No. 2 SUPPL. 2. pp. 48-56.
@article{754c911c4a304677b19ce7e2f401e413,
title = "Neoadjuvant hormonal treatment before radical prostatectomy",
abstract = "Randomized trials evaluating the use of androgen deprivation therapy (ADT) before radical prostatectomy have consistently shown significant decreases in prostate volume and in serum prostate-specific antigen (PSA) levels. All but one study have reported that hormonal pretreatment significantly reduces the incidence of positive surgical margins. However, androgen deprivation does not significantly influence seminal vesicle extension or lymph node involvement nor does it affect tumor grade. The fibrotic reactions that sometimes result from hormonal pretreatment can increase the difficulty of surgery but this has not been emaciated with a higher incidence of perioperative or postoperative complications. In closely monitored clinical trials, bothersome side effects of neoadjuvant hormonal therapy have been limited. Issues that remain to be addressed are the optimal duration of neoadjuvant treatment and whether the benefits of such therapy will translate into improved disease-free survival. At this time, patients with clinical stage T2b disease, PSA elevations greater than 10 to 20 ng/mL, and a high Gleason grade may be considered candidates for neoadjuvant hormonal treatment before surgery.",
keywords = "androgen deprivation therapy, Prostate cancer, radical prostatectomy",
author = "Watson, {R. B.} and Soloway, {M. S.}",
year = "1996",
month = "6",
day = "5",
language = "English",
volume = "14",
pages = "48--56",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "2 SUPPL. 2",

}

TY - JOUR

T1 - Neoadjuvant hormonal treatment before radical prostatectomy

AU - Watson, R. B.

AU - Soloway, M. S.

PY - 1996/6/5

Y1 - 1996/6/5

N2 - Randomized trials evaluating the use of androgen deprivation therapy (ADT) before radical prostatectomy have consistently shown significant decreases in prostate volume and in serum prostate-specific antigen (PSA) levels. All but one study have reported that hormonal pretreatment significantly reduces the incidence of positive surgical margins. However, androgen deprivation does not significantly influence seminal vesicle extension or lymph node involvement nor does it affect tumor grade. The fibrotic reactions that sometimes result from hormonal pretreatment can increase the difficulty of surgery but this has not been emaciated with a higher incidence of perioperative or postoperative complications. In closely monitored clinical trials, bothersome side effects of neoadjuvant hormonal therapy have been limited. Issues that remain to be addressed are the optimal duration of neoadjuvant treatment and whether the benefits of such therapy will translate into improved disease-free survival. At this time, patients with clinical stage T2b disease, PSA elevations greater than 10 to 20 ng/mL, and a high Gleason grade may be considered candidates for neoadjuvant hormonal treatment before surgery.

AB - Randomized trials evaluating the use of androgen deprivation therapy (ADT) before radical prostatectomy have consistently shown significant decreases in prostate volume and in serum prostate-specific antigen (PSA) levels. All but one study have reported that hormonal pretreatment significantly reduces the incidence of positive surgical margins. However, androgen deprivation does not significantly influence seminal vesicle extension or lymph node involvement nor does it affect tumor grade. The fibrotic reactions that sometimes result from hormonal pretreatment can increase the difficulty of surgery but this has not been emaciated with a higher incidence of perioperative or postoperative complications. In closely monitored clinical trials, bothersome side effects of neoadjuvant hormonal therapy have been limited. Issues that remain to be addressed are the optimal duration of neoadjuvant treatment and whether the benefits of such therapy will translate into improved disease-free survival. At this time, patients with clinical stage T2b disease, PSA elevations greater than 10 to 20 ng/mL, and a high Gleason grade may be considered candidates for neoadjuvant hormonal treatment before surgery.

KW - androgen deprivation therapy

KW - Prostate cancer

KW - radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=0029941026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029941026&partnerID=8YFLogxK

M3 - Article

C2 - 8725891

AN - SCOPUS:0029941026

VL - 14

SP - 48

EP - 56

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 2 SUPPL. 2

ER -